Send to

Choose Destination
J Antimicrob Chemother. 2018 Feb 1;73(2):280-286. doi: 10.1093/jac/dkx390.

A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention.

Author information

CHU de Poitiers, Service des Maladies Infectieuses et Tropicales, Poitiers, France.
Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Sorbonne Universités, UPMC Université Paris 06, Inserm UMR S 1135, CNRS ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.
AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Paris, France.
Centre of TB and Lung Diseases, Riga East University Hospital, Riga, Latvia.
State University of Medicine and Pharmacy 'Nicolae Testemitanu', Department of Internal Medicine, Division of Pneumology and Allergology, Chisinau, Republic of Moldova.
National Aspergillosis Centre, University Hospital of South Manchester, Manchester, UK.
Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Division of Clinical Infectious Diseases and German Centre for Infection Research Tuberculosis Unit, Research Centre Borstel, Borstel, Germany.


Chronic pulmonary aspergillosis (CPA) is a severe fungal infection with a high morbidity and mortality, and is usually seen in immunocompetent patients with respiratory disorders. Clinical presentation is nonspecific and often overlaps with the symptoms and the radiological pattern caused by the underlying disease. Clinical management of CPA is further hampered by limited information about the epidemiology, disease dynamics, sensitivity and specificity of different mycological tests, mechanisms of antifungal resistance, efficient treatment and management strategies. In order to contribute to a better understanding and to improve CPA patient management and outcome, we established the Chronic Pulmonary Aspergillosis Network (CPAnet), a self-organized multinational research collaboration. Key research priorities, defined by using a modified Delphi process, include the establishment of a multinational web-based registry, the validation of different diagnostic tests, the establishment of a culture collection from samples of patients with proven CPA and the establishment of a consensus on a treatment outcome definition.


Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center